

Patient: [REDACTED]
DOB: [REDACTED] Age: 67 Sex: M
Patient Identifiers: [REDACTED]
Visit Number (FIN): [REDACTED]

Client: [REDACTED]
Physician: [REDACTED]

ARUP Test Code: 3003684
Collection Date: 06/07/2022
Received in lab: 06/07/2022
Completion Date: 06/08/2022

Test Information

Test performed at NeoGenomics California, 31 Columbia, Aliso Viejo, CA 92656

Patient Report

Patient's report continues on following page(s).



Patient: [REDACTED]
ARUP Accession: 22-158-104742



866.776.5907, option 3

Molecular Genetics
NTRK NGS Fusion Panel

Client: [REDACTED]
ARUP Laboratories

500 Chipeta Way
Salt Lake City, UT 84108
Phone: (800) 242-2787
Fax: (801) 584-5132



FX 4

Patient Name: [REDACTED]
Patient DOB / Sex: [REDACTED] M
Specimen Type: **Unknown**
Body Site: [REDACTED]
Specimen ID: [REDACTED]
MRN: [REDACTED]
Other Patient ID / Acct #: [REDACTED]
Reason for Referral: **diagnosis**

Ordering Physician(s): [REDACTED]
Treating Physician(s): [REDACTED]
Accession / CaseNo: [REDACTED]
Collection Date: **06/07/2022 10:55:00 AM**
Received Date: **06/07/2022 02:47:16 PM EDT**
Report Date: **06/08/2022 09:37:00 AM EST**

Results:

| Fusion | Results | Fusion Partner |
|--------|----------|----------------|
| NTRK1 | Detected | Not Detected |
| NTRK2 | Detected | Not Detected |
| NTRK3 | Detected | Not Detected |

Clinical Significance:

Rearrangements of the genes tested and fusions with partner genes, leading to gene activation and overexpression, have been observed in a variety of cancers. Such fusions may be targetable with selective kinase inhibitors.

Methodology:

Total nucleic acid was extracted from formalin-fixed paraffin-embedded (FFPE) tissue. The NTRK NGS Fusion Panel uses hybridization capture-based targeted next-generation RNA sequencing for detection of fusions involving select exons of the following genes: NTRK1, NTRK2, and NTRK3. Sensitivity may be reduced for detection of fusions with a non-targeted translocation partner and detection of fusions with low expression. Certain isoforms of a given translocation may not be detected. Fusions involving regions with high homology to several regions, including DUX4L1, SUZ12P1 and SXX4 genes, may not be detected.

References:

- Lange AM, Lo HW. Inhibiting TRK Proteins in Clinical Cancer Therapy. *Cancers (Basel)*. 2018;10(4). pii: E105.
- Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol*. 2018;15(12):731-747. PMID: 30333516.

| Test/Panel | MoIDX CPT | AMA CPT |
|-----------------------|-----------|---------|
| NTRK NGS Fusion Panel | 81194 | 81194 |

Electronic Signature

Jerry Drew

The Accessioning Component of this test was performed at NeoGenomics Florida, 12701 Commonwealth Drive, Fort Myers, FL / 33913 / 866-776-5907 / CLIA # 10D0998082. / Medical Director(s): Anahit Nowrouzi, MD. The Technical Component Processing and Analysis of this test was completed at NeoGenomics California, 31 Columbia, Aliso Viejo, CA / 92656 / 866-776-5907 / CLIA #05D1021650 / Medical Director(s): Vladislav Chizhevsky, M.D. The Professional Component of this test was completed at NeoGenomics Florida, 12701 Commonwealth Drive, Fort Myers, FL / 33913 / 866-776-5907 / CLIA # 10D0998082. / Medical Director(s): Anahit Nowrouzi, MD.
The performance characteristics of this test have been determined by NeoGenomics Laboratories. This test has not been approved by the FDA. The FDA has determined such clearance or approval is not necessary. This laboratory is CLIA certified to perform high complexity clinical testing.
Images that may be included within this report are representative of the patient but not all testing in its entirety and should not be used to render a result.
The CPT codes provided with our test descriptions are based on MoIDX and AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.



Patient: [REDACTED]
ARUP Accession: 22-158-104742